CURE​ ​Pharma's​ ​Disruptive​ ​Delivery​ ​Systems​ ​Attracting​ ​Investor​ ​Attention

New drug delivery platforms are needed to fill an essential void in modern medicine

Author's Avatar
Aug 23, 2017
Article's Main Image

It is not every day that we see scientific research innovation that is truly capable of disrupting an entire market sector. But the latest developments at Cure Pharmaceutical Corp. (CURR, Financial) appear to have done just that. The company has made important progress in the traditionally problematic area of drug delivery systems in cancer therapy and designed what could be the most advanced oral thin film on the market today.

Recent product successes and strategic partnership announcements have started to attract investor attention on a growing scale, and measurable progress in these areas has already established the company as an early leader in the space.

Cure Pharmaceutical specializes in creating innovative therapies using differentiated delivery platforms that aid in quicker and more efficient drug consumption for patients. The latest example of this is the company’s CureFilm technology, which is an oral thin film that dissolves in the mouth and allows for improved bioavailability, increased patient compliance and drug administration that is more convenient for all patient types.

This potentially disruptive technology is more stable and durable than other oral thin films competing in the market, and it enables the transmission of multiple active pharmaceutical ingredients or APIs through a single strip.

Need for innovation in developing industries

New drug delivery platforms are needed to fill an essential void in modern medicine. Many patients struggle with dosing accuracy, properly timed absorption rates and the difficulties involved when prescriptions require the consumption of multiple active ingredients at one time. Traditional drug delivery platforms often fail in these areas, as pharmaceutical pills or injections are not always an optimal or convenient option for treating certain types of health conditions.

Studies have shown that up to 40% of adults have difficulty swallowing tablets or pills, and these trends are even more pronounced when treatments are prescribed to children and elderly patients. Patients in underdeveloped countries do not always have access to clean drinking water to take large pharmaceutical pills, and emergency drug administration for unconscious patients is a notoriously difficult practice in all parts of the world. Further problems have been associated with the additives commonly infused with pills and tablets in order to make the active ingredients large enough to be handled by patients.

All of this means that these traditional drug delivery platforms have become insufficient and outdated. What the market needs is disruptive technology that changes the game in ways that improve drug efficiency and improve the quality of life for patients.

Disruptive technologies

At this stage, Cure Pharmaceutical looks to have created the disruptive technology needed to solve many of these problems in traditional medication delivery routes. For investors, the massive potential for upside in the company’s stock represents a rare opportunity to generate returns, given the number of different businesses these products will likely influence. The CureFilm technology offers a unique form factor for patient-specific dosing, and this is a product that has the potential to replace injections and infusions in many areas.

hWs_kpZNgipheZ7OJViP9UsPAHE2M4S4p8uITC2ztHwGsI8lhyk8GZ54osT7z4xyd7UjtWMs3YSLhqTmClFN2TbAqUIHj6NOjYcb5oK1gG4DCSHM-c1_adQOs7LM9XzzfeBkKfXS

The company operates in a number of additional markets (i.e., medical foods, nutraceuticals and animal health products) and so we expect the company’s product pipeline to be quite diverse going forward. As a fully integrated pharmaceutical bioscience organization, Cure Pharma’s mission statement shows that its goals are expansive, as the company aims "to change the way that quality medicines are delivered to people in need, regardless of geography or economic status."

For biotech investors, these are the types of goals that should continue to attract attention in the years to come. The market has a clear need for more efficient and effective drug delivery systems, and these leading product innovations from Cure Pharmaceutical Corp. look to possess the capabilities required to overcome obstacles in the traditional paths to patient treatment and medication.

Disclosure: The author has no position in any asset mentioned.